Nitro reduction as an electronic switch for bioreductive drug activation.
It is well known that the reduction of aromatic nitro groups can give rise to toxic species, and that net nitro reduction by one-electron reductases can usually be inhibited by oxygen. There has been much interest in utilizing this biotransformation to activate drugs in hypoxic regions of tumors, but no clinically useful compound has yet resulted. Nitroreductive activation of prodrugs by oxygen-insensitive (and oxygen-sensitive) reductases is also of current interest because of new methods for introducing specific nitroreductases into tumors (e.g., as antibody-enzyme conjugates or by gene therapy). In most of the compounds investigated previously, cytotoxicity appears to be due to reactive nitroso or hydroxylamine reduction products arising from the nitro group itself. It is argued that there is greater scope for designing potent and selective nitro compounds by using the nitro group as an electronic switch to activate a latent reactive moiety elsewhere in the molecule. Examples of this approach include the nitro(hetero)aromatic mustards (e.g., SN 23816, NSC 646394) in which the nitro group controls the reactivity of a nitrogen mustard to which it is directly conjugated, and the nitro(hetero)aromatic methylquaternary (NMQ) mustards (e.g., SN 25341, NSC 658926) in which reduction of the nitro group triggers fragmentation of the molecule to release a reactive aliphatic nitrogen mustard. Many of these compounds show very high selectivity for hypoxic cells in culture. Some are also active against hypoxic cells in tumors, and provide large tumor growth delays when combined with tumor blood flow inhibitors such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA). These prodrug designs also have potential for releasing effectors other than nitrogen mustards, which opens up many possibilities for use of nitro compounds as tumor-selective prodrugs.
Siim
B G
BG
Department of Pathology, University of Auckland, New Zealand. b.siim@auckland.ac.nz
Denny
W A
WA
Wilson
W R
WR
D000818:Animals; D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000493:pharmacokinetics; D000970:Antineoplastic Agents / Q000378:metabolism / Q000493:pharmacokinetics*; D001711:Biotransformation; D004563:Electrochemistry; D006801:Humans; D009574:Nitro Compounds / Q000378:metabolism / Q000493:pharmacokinetics*; D010084:Oxidation-Reduction; D011355:Prodrugs / Q000378:metabolism / Q000493:pharmacokinetics*; D011838:Radiation-Sensitizing Agents / Q000378:metabolism / Q000493:pharmacokinetics
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D009574:Nitro Compounds; D011355:Prodrugs; D011838:Radiation-Sensitizing Agents